Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Find a clinical trial that's recruiting now
Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.
- 24,857
- trials recruiting now
- 14%
- of all US trials open to enrollment
- 52
- states with recruiting sites
A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.
Popular conditions
Showing the 40 largest recruiting trials by target enrollment in South Dakota. Use the search field to focus on a condition or drug.
Helix Research Network
Helix
NCT06057181
Connect for Cancer Prevention Study (Connect)
National Cancer Institute (NCI)
NCT04609072
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
University of California, San Francisco
NCT02620852
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
Sanford Health
NCT04477928
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Sanford Health
NCT01793168
Umbrella Study for Analysis of Data Related to Patients With Cancer
Tempus AI
NCT06018753
Investigations of Reproductive Cancers in Women
PinkDx
NCT06527157
Genetic Epidemiology of Rotator Cuff Tears: The cuffGEN Study
University of Michigan
NCT04831164
MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.
Carolyn M Hettrich
NCT02075775
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
University of Kansas Medical Center
NCT06425848
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Merck Sharp & Dohme
NCT04165798
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation
NCT07069738
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Eli Lilly and Company
NCT07153471
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development
NCT07225946
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
NCT06324357
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
NCT07022483
Melodi Matrix™ in Breast Reconstruction
Melodi Health
NCT06027996
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity
NCT06757634
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Tempus AI
NCT07154823
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
NCT06646276
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Melt Pharmaceuticals
NCT06383273
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Merck Sharp & Dohme
NCT06305754
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT06915025
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines
NCT07252232
Pounce™ Thrombectomy System Retrospective Registry
SurModics
NCT05868161
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
NCT04221542
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Incyte Corporation
NCT07214779
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
NCT06614192
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme
NCT04165070
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Rakuten Medical
NCT06699212
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Takeda
NCT06227910
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Amgen
NCT07037758
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme
NCT02332668
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT07160725
Perform Humeral System Study
Stryker Trauma and Extremities
NCT05067543
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
Eli Lilly and Company
NCT07223840
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
NCT06787612
Read our methodology - how recruiting status is sourced and refreshed from the public registry.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.